For U.S. Healthcare Professionals only
Patient Site
Indications

Indication

AUGTYRO^TM (repotrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
U.S. Full Prescribing Information
Patient Information
Patient Site

Home
Efficacy
Safety Profile
Study Design
Initiation & Dosing
Support & Resources
- Access & Support
- Resources
REQUEST A REP

REQUEST A REP

SITE MAINTENANCE

THIS SITE IS CURRENTLY UNDERGOING SCHEDULED MAINTENANCE.

Please check back at a later time, or go to BMS.com.

Legal Notice
Privacy Policy

This site is intended for U.S. Healthcare Professionals only.

© 2024 Turning Point Therapeutics, Inc., a Bristol Myers Squibb company.

AUGTYRO^TM and the related logo are trademarks of Turning Point Therapeutics, Inc.

3600-US-2400184 07/24

BACK TO TOP